|
HERD: A multi-centre prospective cohort study to facilitate early detection of relapse in radically treated, high risk head and neck squamous cell carcinoma. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - GlaxoSmithKline |
|
|
Stock and Other Ownership Interests - Mission Therapeutics; Storm Therapeutics |
Patents, Royalties, Other Intellectual Property - IP related to diagnostics filed and managed by Cancer Research UK |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - AstraZeneca (Inst) |
Other Relationship - Cancer Research UK |
(OPTIONAL) Uncompensated Relationships - MSD Oncology |
|
|
No Relationships to Disclose |
|
|
Honoraria - Boehringer Ingelheim; Pfizer; Tesaro |
Travel, Accommodations, Expenses - Conquer Cancer Foundation; GlaxoSmithKline UK Ltd. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Therapanacea (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |